The pharmaceutical community is abuzz about the new drug, a dual-action medication showing remarkable outcomes in preliminary trials . This innovative compound, a glucagon-like peptide-1 activator alongside a glucose-dependent insulinotropic compound, appears to effectively decrease body weight and positively affect metabolic markers. Experts are p